Celladon hauls in $53M for heart-failure program; Vax developer Intercell eyes $26.1M deal;

 @FierceBiotech: Honeybee substance freezes prostate cancer growth (Hint: it's not honey). More | Follow @FierceBiotech

 @RyanMFierce: Talon takes it in the teeth, back to penny stock, after FDA says more time needed to review lead cancer drug. Article | Follow @RyanMFierce

> San Diego-based Celladon has brought in $53 million through a second close of a financing round that was initially announced earlier this year. Item

> Vaccine developer Intercell, based in Austria, has struck a deal with Swiss firm BB Biotech as part of its plans to raise $26.1 million to sure up its financial position. Report

> In a deal that includes pre-commercialization fees of $3 million, Pozen ($POZN) has licensed certain European rights to its migraine treatment to Desitin Arzneimittel. Item

 @FiercePharma: Some Revlimid patients at higher risk of other blood cancers compared w/ placebo, FDA says--Story. | Follow @FiercePharma

> Docs riled by FDA's proposal to open up drug access. More

> Europe may be austere, but it's also hiring in pharma. Story

> Novartis may weigh Lucentis price cut in U.K. Article

> Abbott to pay $1.6B to wrap up Depakote marketing probe. News

Medical Devices News

 @FierceMedDev: Baxter is facing an SEC subpoena for records of its 2010 pump recall. More | Follow @FierceMedDev

> Boston Scientific's CEO: CRM business in active rebuilding mode. Article

> Canada's Monteris snags $9M in investments for NeuroBlate. News

> Dutch test boosts prospects for photoacoustic breast imaging device. Story

> Allergan subpoenaed over Lap-Band obesity device. More

Pharma Manufacturing News

> Baxter bitten again by problems with Colleague infusion pumps. News

> Pfizer to grow manufacturing capacity in Indonesia. Article

> Sanofi closing plant in Missouri, 4 years later than expected. More

> BASF erecting 50,000-ton-plus formic acid plant in Louisiana. Story

Biotech Research News

> Researchers find key to premature aging syndrome. Spotlight

> Controversial bird flu study details revealed. Article

> Stem cells grown from skin treat muscular dystrophy in mice. News

> Stem cell/gene therapy holds HIV at bay in mouse trials. More

And Finally… Retrophin, a biotech startup focused on rare-disease treatments, has raised $4 million in a Series A round led by MSMB Capital. Release

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.